MedPath

Investigation of factors affecting patients' preference of biologics treatment modes with rheumatoid arthritis

Not Applicable
Conditions
rheumatoid arthritis
Registration Number
JPRN-UMIN000042203
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
400
Inclusion Criteria

Not provided

Exclusion Criteria

No specific criteria

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Factors affecting the preference of treatment modes of rheumatoid arthritis patients using biologic disease-modifying antirheumatic drugs.
Secondary Outcome Measures
NameTimeMethod
*Presence or absence of a gap from the current treatment modes. *Factors which desire to change the treatment modes in the future.
© Copyright 2025. All Rights Reserved by MedPath